Seminars in Perinatology
Volume 31, Issue 4 , Pages 262-271 , August 2007

Blood Product Replacement in the Perinatal Period

  • YanYun Wu, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Yan Yun Wu, MD, PhD, Department of Laboratory Medicine, Yale University School of Medicine, 20 York Street, CB-459, New Haven, CT 06504.
    • ,
  • Gary Stack, MD, PhD

References 

  1. Judd WJ. Guidelines for Prenatal and Perinatal Immunohematology. Bethesda, MD: AABB Press; 2006;
  2. American Academy of Pediatrics: Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics. 1994;94:558–565
  3. Voak D, Bowley CC. A detailed serological study on the prediction and diagnosis of ABO hemolytic disease of the newborn (ABO HD). Vox Sang. 1969;17:321–348
  4. Wong EC, Luban NL. Intrauterine, neonatal, and pediatric transfusion. In:  Mintz PD editors. Transfusion Therapy: Clinical Principles and Practice. (ed 2). Bethesda, MD: AABB Press; 2005;p. 159–201
  5. Cassandra DJ, Strauss RG. Transfusion of neonates and pediatric patients. In:  Hillyer CD,  Silberstein LE,  Ness PM, et al. editor. Blood Banking and Transfusion Medicine: Basic Principles and Practice. (ed 2). Philadelphia, PA: Churchill Livingstone; 2007;p. 510–522
  6. Strauss RG. Neonatal red blood cell, platelet, plasma, and neutrophil transfusions. In:  Simon TL,  Dzik WH,  Snyder EL, et al. editor. Rossi’s Principles of Transfusion Medicine. (ed 3). Philadelphia, PA: Lippincott Williams & Wilkins; 2002;p. 486–498
  7. Brown KA, Bissonnette B, McIntyre B. Hyperkalemia during rapid blood transfusion and hypovolaemic cardiac arrest in children. Can J Anaesth. 1990;37:747–754
  8. Hall TL, Barnes A, Miller JR, et al. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfus Apheresis Sci. 1993;33:606–609
  9. Eder A, Hume H, Pisciotto P, et al. Adverse effects of blood transfusion. In:  Roseff SD editors. Pediatric Transfusion: A Physician’s Handbook. (ed 2). Bethesda, MD: AABB Press; 2006;p. 139–178
  10. Stockman JA, de Alarcon PA. Overview of the state of the art of Rh disease: history, current clinical management, and recent progress. J Pediatr Hematol Oncol. 2001;23:385–393
  11. Petz LD, Garratty G. Immune Hemolytic Anemias. (ed 2). Philadelphia, PA: Churchill Livingstone; 2004;
  12. Moise KJ. Management of Rhesus alloimmunization in pregnancy. Obstet Gynecol. 2002;100:600–611
  13. Bracey AW, Moise KJ. Hemolytic disease of the fetus or newborn: Treatment and prevention. In:  Simon TL,  Dzik WH,  Snyder EL editor. Rossi’s Principles of Transfusion Medicine. (ed 3). Philadelphia, PA: Lippincott, Williams and Wilkins; 2002;
  14. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation (Clinical practice guideline). Pediatrics. 2004;114:297–316
  15. Poole J, Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev. 2007;21:58–71
  16. Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook. (ed 2). 2003;
  17. Voak D. The serological specificity of the sensitizing antibodies in ABO heterospecific pregnancy of the group O mother. Vox Sang. 1968;14:271–281
  18. Ozolek JA, Watchko JF, Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr. 1994;125:87–91
  19. Vaughan JI, Manning M, Warwick RM, et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998;338:338
  20. Wagner T, Resch B, Reiterer F, et al. Pancytopenia due to suppressed hematopoiesis in a case of fatal hemolytic disease of the newborn associated with anti-K supported by molecular K1 typing. J Pediatr Hematol Oncol. 2004;26:13–15
  21. Babinszki A, Lapinski RH, Berkowitz RL. Prognostic factors and management in pregnancies complicated with severe Kell alloimmunization: experiences of the last 13 years. Am J Perinatol. 1998;15:695–701
  22. Dhodapkar KM, Blei F. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J Pediatr Hematol Oncol. 2001;23:69–70
  23. Judd WJ. Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion. 2001;41:1445–1452
  24. Bowman J. Rh-immunoglobulin: Rh prophylaxis. Best Pract Res Clin Haematol. 2006;19:27–34
  25. Hartwell EA. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998;110:281–282
  26. Bianchi DW, Avent ND, Costa J-M, et al. Noninvasive prenatal diagnosis of fetal Rhesus D. Obstet Gynecol. 2005;106:841–844
  27. Gall SA, Miller JM. Rh isoimmunization: a 24 year experience at Duke University Medical Center. Am J Obstet Gynecol. 1981;140:902–908
  28. Van Dijk BA, Dooren MC, Overbeeke MA. Red cell antibodies in pregnancy: there is no “critical titre.”. Transfus Med. 1995;5:199–202
  29. Oepkes D, Seaward PG, Vandenbussche FPHA, et al. Doppler ultrasonography versus amniocentesis to predict fetal anemia. N Engl J Med. 2006;355:156–164
  30. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev. 2002;16:69–72
  31. In:  Klein HG,  Anstee DJ editor. Mollison’s Blood Transfusion in Clinical Medicine. (ed 11). Malden, MA: Blackwell Publishing; 2005;p. 581–584
  32. In:  Brecher ME editors. Perinatal Issues in Transfusion Practice: Technical Manual. (ed 15). Bethesda, MD: AABB Press; 2005;p. 551–553
  33. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–366
  34. Davoren A, Curtis BR, Aster RH, et al. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion. 2004;44:1220–1225
  35. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92:2280–2287
  36. L’Abbe D, Tremblay L, Filion M, et al. Alloimmunization to platelet antigen HPA-1a (PlA1) is strongly associated with both HLA-DRB3*0101 and HLA-DQB1*0201. Hum Immunol. 1992;34:107–114
  37. Saito S, Ota M, Komatsu Y, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion. 2003;43:908–917
  38. Thude H, Schorner U, Helfricht C, et al. Neonatal alloimmune thrombocytopenia caused by human leucocyte antigen-B27 antibody. Transfus Med. 2006;16:143–149
  39. Rousseau J, Goldman M, David M. HPA-5b (Bra) neonatal alloimmune thrombocytopenia in Quebec: incidence and clinical outcome in 31 cases. Transfusion. 2004;44:844–848
  40. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1:363–366
  41. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang. 2003;84:318–325
  42. McFarland JG. Detection and identification of platelet antibodies in clinical disorders. Transfus Apheresis Sci. 2003;28:297–305
  43. Berkowitz RL, Kolb EA, McFarland JG, et al. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol. 2006;107:91–96
  44. Yinon Y, Spira M, Solomon O, et al. Antenatal noninvasive treatment of patients at risk for alloimmune thrombocytopenia without a history of intracranial hemorrhage. Am J Obstet Gynecol. 2006;195:1153–1157
  45. Thung SF, Grobman WA. The cost effectiveness of empiric intravenous immunoglobulin for the antepartum treatment of fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2005;193:1094–1099
  46. Sandler SG, Johnson VV, Ramasethu J. Washed and volume-reduced blood components. In:  Hillyer CD,  Silberstein LE,  Ness PM, et al. editor. Blood Banking and Transfusion Medicine (Basic Principles and Practice). (ed 2). Philadelphia, PA: Churchill Livingstone; 2007;
  47. Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood. 2006;107:3761–3763
  48. Schallmoser K, Kutschera J, Macher S, et al. Delayed detectability of anti-HPA-3a by the MAIPA assay in a severe neonatal alloimmune thrombocytopenia, but successful transfusion of incompatible donor platelets: a case report. Vox Sang. 2006;91:181–183

PII: S0146-0005(07)00063-8

doi: 10.1053/j.semperi.2007.05.004

Seminars in Perinatology
Volume 31, Issue 4 , Pages 262-271 , August 2007

Article Tools